LILRB4 and neoplasm: In addition, LILRB4 has been reported to be expressed on non-small cell lung cancer to promote angiogenesis, invasion and metastasis [42], on osteoclast to inhibit differentiation and maturation of osteoclast [43], on several B lineage cells including plasma cells and plasmablasts (in particular those from lupus patients) [44], MLL-rearranged B-ALL, and on B-cell chronic lymphocytic leukemia (CLL) cells to control tumor progression [45].